Protalix Biotherapeutics Inc V.PLX.H

Primary Symbol: PLX

Healthcare Biotechnology

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

NYSEAM:PLX - Post by User

Protalix Biotherapeutics Inc > Nice trade. Repeat until rich

<< Previous

Bullboard Posts

Next >>

Post by Maxmoeon Sep 14, 2018 8:01am

102 Views

Post# 28618568

Nice trade. Repeat until rich

Sold two small pieces of Gilby purchase for 100% of purchase price. Nice trade! We get to keep vast majority of gilby assets for free. I’m looking forward to some drill results next quarter that have the potential to blow the doors off the current NAV. I can’t think of another industry in Canada that consistently produces more millionaires.

<< Previous

Bullboard Posts

Next >>

Yukon agency detects cyanide near Victoria Gold's Eagle mine